Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
42.3M
-
Number of holders
-
72
-
Total 13F shares, excl. options
-
20.5M
-
Shares change
-
+520K
-
Total reported value, excl. options
-
$351M
-
Value change
-
+$9.47M
-
Number of buys
-
34
-
Number of sells
-
-25
-
Price
-
$17.12
Significant Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) as of Q3 2022
80 filings reported holding TARS - Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q3 2022.
Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) has 72 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.5M shares
of 42.3M outstanding shares and own 48.47% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (2.26M shares), TANG CAPITAL MANAGEMENT LLC (2.09M shares), RTW INVESTMENTS, LP (2.02M shares), Cormorant Asset Management, LP (1.97M shares), Frazier Life Sciences Management, L.P. (1.79M shares), TimesSquare Capital Management, LLC (1.52M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.32M shares), PERCEPTIVE ADVISORS LLC (1.3M shares), BlackRock Inc. (1.12M shares), and VANGUARD GROUP INC (936K shares).
This table shows the top 72 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.